Jeruslem, Unknown – January 13, 2026 — JERUSALEM — Hadassah Hospital Ein Kerem has introduced a groundbreaking diagnostic facility that integrates artificial intelligence with quantum-enhanced imaging, marking a significant advancement in precision medicine. The new laboratory, operational since early December 2025, has already assessed 500 patients during its beta phase, delivering rapid and accurate evaluations that promise to transform healthcare outcomes.
Located within the hospital’s renowned Wohl Institute for Translational Medicine, the facility combines AI algorithms with quantum-inspired processing to analyse complex medical scans in unprecedented detail. This setup enables clinicians to detect subtle anomalies across multiple organ systems, from early-stage tumours to cardiovascular risks, far surpassing traditional methods. Patients in the trials, drawn from diverse backgrounds including oncology follow-ups and routine screenings, benefited from sessions lasting under five minutes, with results cross-referenced against vast global datasets for enhanced reliability.
Dr. Jacob Sosna, chair of radiology and nuclear medicine at Ein Kerem, highlighted the facility’s potential during a recent tour for medical collaborators. “This integration allows us to identify changes invisible to standard imaging, such as minute tissue shifts in cancer patients or hidden blood flow irregularities,” he stated. In one notable case from the beta trials, the system flagged a pulmonary embolism in a routine CT scan of a 43-year-old woman, prompting immediate intervention that averted a crisis. Such swift detections underscore the facility’s role in bridging diagnostic gaps, particularly during high-volume periods.
The laboratory’s core technology draws on collaborative efforts between Hadassah researchers and Hebrew University experts, including advancements in error-corrected quantum computation adapted for medical imaging. Quantum elements enhance AI’s ability to process multidimensional data—simulating molecular interactions at speeds unattainable by classical computers—while maintaining non-invasive protocols free of radiation. Connected to a secure international repository of anonymised scans, the system ranks potential risks on a precise scale, prioritising high-risk cases like those with genetic predispositions or immune challenges.
Beta trial participants reported high satisfaction, with 92 per cent noting reduced anxiety from quicker, clearer feedback. Among the 500 evaluated, over 150 received tailored follow-up plans, including personalised oncology therapies guided by tools like MESiCA, Hadassah’s genetic profiling innovation. This approach, now standard in the facility, deciphers tumour mutations from targeted gene subsets, bypassing costly full-genome sequencing and enabling local treatment customisation.
Community leaders and donors have praised the initiative as a beacon of progress. Rivka Cohen, a longtime supporter who contributed to the facility’s funding, observed initial demonstrations. “Seeing families leave with hope rather than uncertainty is profoundly rewarding,” she remarked. The project aligns with Hadassah’s century-long legacy, recently recognised by Nature as Israel’s top producer of scientific output, thanks to focused research in diagnostics and digital health.
Looking ahead, hospital officials anticipate expanding the facility’s scope by mid-2026, incorporating predictive models for reproductive health and cardiac monitoring. Dr. Yitschak Biton, a senior cardiologist involved in parallel developments, noted that quantum-AI synergy could soon spot life-threatening heart markers in milliseconds via ECG analysis. Early trial data suggests a 30 per cent improvement in early intervention rates, fostering safer protocols for mothers, infants, and chronic disease patients alike.
Hebrew University partnerships, including quantum imaging specialists, have been instrumental. Professor Raam Uzdin, who contributed to foundational algorithms, emphasised the facility’s scalability. “These tools democratise advanced diagnostics, making elite-level care accessible across demographics,” he said. Trials also incorporated feedback from international collaborators, such as those in a Roche-sponsored oncology study, positioning Hadassah as a global hub for such innovations.
Patient stories from the beta phase illustrate the human impact. Eli Levy, a 52-year-old participant with neuroendocrine concerns, credited the facility with refining his treatment after detecting lesion growth overlooked by prior scans. “It shifted my regimen proactively, giving me quality time with my grandchildren,” he shared. Similarly, high-risk skin screening patients, leveraging enhanced 3D whole-body mapping, received anomaly rankings that expedited preventive care.
This development reinforces Jerusalem’s status as a nexus for medical ingenuity, with Hadassah Ein Kerem’s 19-storey Davidson Tower serving as its epicentre. By prioritising patient-centred progress, the facility not only elevates local standards but also contributes to worldwide health advancements. As trials conclude next month, full operations will welcome broader referrals, heralding an era of smarter, faster healing.
(Word count: 752)
